Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREOur mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORECareers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSPhysician experiences with biosimilars have increased substantially in Europe over the past few years, driven by an increased policy focus, greater comfort, and regulatory guidance. These biosimilars have also provided savings for the overall health system and have played a crucial role in enhancing sustainability of this system. Several new biosimilars are expected to launch over the next five years and ensuring their optimal use will be important.
Understanding physician perspectives on biosimilars is an important part of developing a sustainable competitive market, as these perspectives drive the overall use. This report aims to understand the experience of physicians that have been utilizing biosimilars and the perspectives of physicians that will be using them for the first time in the near future. These insights were gathered through physician surveys in select European countries, and they hold lessons for stakeholders across the healthcare system on how to optimize the use of biosimilars and overcome physician concerns.
An important shift that can be seen in the data is the evolution of the perception of biosimilars. It was found that 63% of physicians reported their perceptions of biosimilars had evolved over time, and perceptions seem to have become more positive.
Based on discussions with some physicians, even the physicians who were not well informed about biosimilars had a positive perception driven by EMA statements and other news that they had come across. These findings suggest a relatively higher degree of awareness and perception compared to other studies from 2014 to 2018.
When asked about their main concerns that would limit prescribing biosimilars in the first year of availability, physicians stated efficacy, safety, bio-comparability, and the need to gather more information as the main factors.
Foundational Analytics on Emerging Risks to Sustainability
Achieving Sustainable Levels of Biosimilar Competition in Europe
Competition, Savings, and Sustainability
Building resilience in cancer screening and diagnostics in Europe based on lessons from the pandemic
Where IQVIA’s RWE Academy On Call can play an integral role
Details behind the steady rise in treatment and utilization, and the role of the COVID-19 vaccine on volume and behavior
Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.